412 related articles for article (PubMed ID: 27143511)
1. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
[No Abstract] [Full Text] [Related]
2. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
3. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
Matsuoka T; Yashiro M
World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
[TBL] [Abstract][Full Text] [Related]
4. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
5. TGF-β signaling in liver and gastrointestinal cancers.
Katz LH; Likhter M; Jogunoori W; Belkin M; Ohshiro K; Mishra L
Cancer Lett; 2016 Sep; 379(2):166-72. PubMed ID: 27039259
[TBL] [Abstract][Full Text] [Related]
6. Personalized treatment approach to gastroenteropancreatic neuroendocrine tumors: a medical oncologist's perspective.
Paul D; Ostwal V; Bose S; Basu S; Gupta S
Eur J Gastroenterol Hepatol; 2016 Sep; 28(9):985-90. PubMed ID: 27257869
[TBL] [Abstract][Full Text] [Related]
7. Targeted molecular ablation of cancer stem cells for curing gastrointestinal cancers.
Kim YS; Lee HJ; Park JM; Han YM; Kangwan N; Oh JY; Lee DY; Hahm KB
Expert Rev Gastroenterol Hepatol; 2017 Nov; 11(11):1059-1070. PubMed ID: 28707966
[TBL] [Abstract][Full Text] [Related]
8. Advances in Molecular Pathology and Treatment of Periampullary Cancers.
Chandrasegaram MD; Chen JW; Price TJ; Zalcberg J; Sjoquist K; Merrett ND
Pancreas; 2016 Jan; 45(1):32-9. PubMed ID: 26348463
[TBL] [Abstract][Full Text] [Related]
9. The Role of the Hedgehog Pathway in Chemoresistance of Gastrointestinal Cancers.
Liang Y; Yang L; Xie J
Cells; 2021 Aug; 10(8):. PubMed ID: 34440799
[TBL] [Abstract][Full Text] [Related]
10. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.
Giordani E; Zoratto F; Strudel M; Papa A; Rossi L; Minozzi M; Caruso D; Zaccarelli E; Verrico M; Tomao S
Curr Cancer Drug Targets; 2016; 16(2):175-85. PubMed ID: 26278713
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
Pishvaian MJ; Brody JR
Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
[TBL] [Abstract][Full Text] [Related]
12. Updates in Tumor Profiling in Gastrointestinal Cancers.
Perez K; Safran HP
R I Med J (2013); 2015 Oct; 98(10):21-4. PubMed ID: 26422541
[TBL] [Abstract][Full Text] [Related]
13. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road.
Iovanna J; Dusetti N
Cancer Lett; 2017 Dec; 410():63-67. PubMed ID: 28947138
[TBL] [Abstract][Full Text] [Related]
14. Aquaporins: Their role in gastrointestinal malignancies.
Nagaraju GP; Basha R; Rajitha B; Alese OB; Alam A; Pattnaik S; El-Rayes B
Cancer Lett; 2016 Apr; 373(1):12-18. PubMed ID: 26780474
[TBL] [Abstract][Full Text] [Related]
15. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
Lee H; El Jabbour T; Ainechi S; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon SH; Ali SM; Schrock A; Fabrizio D; Frampton G; Nazeer T; Miller VA; Stephens PJ; Ross JS
Hum Pathol; 2017 Dec; 70():84-91. PubMed ID: 29079173
[TBL] [Abstract][Full Text] [Related]
16. piRNA: A promising biomarker in early detection of gastrointestinal cancer.
Ameli Mojarad M; Ameli Mojarad M; Shojaee B; Nazemalhosseini-Mojarad E
Pathol Res Pract; 2022 Feb; 230():153757. PubMed ID: 34998210
[TBL] [Abstract][Full Text] [Related]
17. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of liver cancer and personalized therapy.
Li L; Wang H
Cancer Lett; 2016 Sep; 379(2):191-7. PubMed ID: 26213370
[TBL] [Abstract][Full Text] [Related]
19. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.
Birnbaum DJ; Bertucci F; Finetti P; Birnbaum D; Mamessier E
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):248-255. PubMed ID: 29499330
[TBL] [Abstract][Full Text] [Related]
20. Novel Holistic Approaches for Overcoming Therapy Resistance in Pancreatic and Colon Cancers.
Sarkar FH
Med Princ Pract; 2016; 25 Suppl 2(Suppl 2):3-10. PubMed ID: 26228733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
